IRBM
Wednesday, June 05, 2024
Multiple Therapeutics
Company Presentation Theater 2
RBM stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate.
With a history of contributing to four approved drugs, and it’s own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.
Company Website:
https://www.irbm.com/
Lead Product in Development:
We have two lead programs, one is a potential best in class brain-penetrant SHP2 inhibitor (pre-clinical phase), and the other is a first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in “Ph-like” B-ALL (discovery phase)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Company HQ City
Pomezia
Company HQ State
Lazio
Company HQ Country
Italy
CEO/Top Company Official
Ilaria Di Lorenzo
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
.png)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())